Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUENASDAQ:CUENASDAQ:QNCXNASDAQ:UBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.97$4.53$3.20▼$28.60$48.67M0.27432,881 shsN/ACUECue Biopharma$0.64+3.4%$0.73$0.45▼$1.99$48.30M1.51423,909 shs43,814 shsQNCXQuince Therapeutics$1.13+3.2%$1.07$0.51▼$2.45$51.15M0.83287,646 shs103,519 shsUBXUnity Biotechnology$0.71-1.6%$0.90$0.66▼$3.10$12.24M1.28129,308 shs16,406 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%-0.20%+25.19%+20.92%-74.34%CUECue Biopharma-1.85%-1.67%-20.33%-42.06%-60.26%QNCXQuince Therapeutics+3.81%+2.83%0.00%-27.33%+27.95%UBXUnity Biotechnology+1.02%+6.08%-32.49%-58.95%-54.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUEbluebird bio3.1612 of 5 stars3.15.00.00.02.41.71.3CUECue Biopharma3.8143 of 5 stars3.52.00.04.70.60.81.3QNCXQuince Therapeutics3.5291 of 5 stars3.65.00.00.02.41.71.3UBXUnity Biotechnology4.3172 of 5 stars3.34.00.04.72.60.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.25Hold$44.60797.38% UpsideCUECue Biopharma 3.00Buy$3.00368.02% UpsideQNCXQuince Therapeutics 3.29Buy$8.00611.11% UpsideUBXUnity Biotechnology 2.50Moderate Buy$3.75427.43% UpsideCurrent Analyst Ratings BreakdownLatest UBX, CUE, BLUE, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/27/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.00 ➝ $2.005/16/2025UBXUnity BiotechnologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$6.00 ➝ $1.004/23/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/23/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/25/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $4.003/25/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/24/2025QNCXQuince TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.003/24/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/10/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CUECue Biopharma$7.99M6.04N/AN/A$0.82 per share0.78QNCXQuince TherapeuticsN/AN/AN/AN/A$1.98 per shareN/AUBXUnity Biotechnology$240K50.99N/AN/A$1.69 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/14/2025 (Estimated)CUECue Biopharma-$50.73M-$0.67N/AN/AN/A-468.02%-156.38%-88.07%8/13/2025 (Estimated)QNCXQuince Therapeutics-$31.39M-$1.39N/AN/AN/AN/A-53.27%-22.73%8/12/2025 (Estimated)UBXUnity Biotechnology-$39.86M-$1.62N/AN/AN/AN/A-119.70%-45.86%7/22/2025 (Estimated)Latest UBX, CUE, BLUE, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025QNCXQuince Therapeutics-$0.24-$0.34-$0.10-$0.34N/AN/A5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million4/22/2025Q1 2025UBXUnity Biotechnology-$0.43-$0.43N/A-$0.43N/AN/A3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/24/2025Q4 2024QNCXQuince Therapeutics-$0.19-$0.28-$0.09-$0.28N/A$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/AUBXUnity BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33CUECue Biopharma0.052.222.22QNCXQuince Therapeutics0.339.539.53UBXUnity BiotechnologyN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%CUECue Biopharma35.04%QNCXQuince Therapeutics30.75%UBXUnity Biotechnology29.49%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%CUECue Biopharma10.78%QNCXQuince Therapeutics20.30%UBXUnity Biotechnology5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCUECue Biopharma6075.35 million55.58 millionOptionableQNCXQuince Therapeutics6045.47 million36.61 millionOptionableUBXUnity Biotechnology6017.21 million15.87 millionOptionableUBX, CUE, BLUE, and QNCX HeadlinesRecent News About These CompaniesHC Wainwright Issues Positive Estimate for UBX EarningsMay 30, 2025 | americanbankingnews.comUnity Biotechnology (NASDAQ:UBX) Earns Neutral Rating from HC WainwrightMay 29, 2025 | americanbankingnews.comHC Wainwright & Co. Downgrades Unity Biotechnology (UBX)May 28, 2025 | msn.comUnity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho SecuritiesMay 18, 2025 | theglobeandmail.comBay Area biotech company Unity lays off every single worker, including CEOMay 7, 2025 | msn.comBay Area biotech company Unity, once worth $700M, lays off entire remaining workforceMay 5, 2025 | msn.comSouth San Francisco biotech company lays off entire workforce, including CEOMay 5, 2025 | msn.comUnity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 rolesMay 5, 2025 | fiercebiotech.comUNITY Biotechnology to Present at the ARVO 2025 Annual MeetingMay 1, 2025 | globenewswire.comNEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325April 25, 2025 | ophthalmologytimes.comUNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business UpdatesApril 22, 2025 | globenewswire.comUnity Biotechnology price target lowered to $4 from $8 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology price target lowered to $4 from $6 at ChardanMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology announces results from ASPIRE Phase 2b study in DMEMarch 25, 2025 | markets.businessinsider.comUnity reports topline outcomes from trial of diabetic macular oedema therapyMarch 25, 2025 | msn.comUNITY Biotechnology tanks on mixed results for eye disease drugMarch 25, 2025 | thepharmaletter.comUBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyMarch 25, 2025 | zacks.comUNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular EdemaMarch 24, 2025 | finance.yahoo.comUnity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edemaMarch 24, 2025 | ophthalmologytimes.comUNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trialMarch 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeUBX, CUE, BLUE, and QNCX Company Descriptionsbluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Cue Biopharma NASDAQ:CUE$0.64 +0.02 (+3.39%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Quince Therapeutics NASDAQ:QNCX$1.13 +0.04 (+4.04%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Unity Biotechnology NASDAQ:UBX$0.71 -0.01 (-1.58%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable Alphabet Stock Analysis: What's Next—Bull or Bear Market? TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
